Everence Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Everence Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,990	Closed	-$394K	–	864
2025 Q1	$394K	Hold	2,990	–	–	0.03%	440
2024 Q4	$250K	Buy	+2,990	New	+$246K	0.02%	673

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Everence Capital Management's ITCI Position: Q2 2025 in Review

Everence Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,990 shares — an estimated $394K sold.

Everence Capital Management first reported a position in ITCI in Q4 2024 and held it in 2 quarters. The position peaked at $394K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Everence Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Everence Capital Management sold 2,990 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $394K.
Everence Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 2 quarters.
Everence Capital Management's Intra-Cellular Therapies Inc. position peaked at $394K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Everence Capital Management's 13F filing for Q2 2025, filed 29 Jul 2025.